Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article

Advertisement

ResearchIn-Press PreviewImmunologyInfectious diseaseVirology Open Access | 10.1172/JCI203771

HVEM-LIGHT signaling promotes antibody-dependent neutrophil FcγR-mediated trogocytosis against herpes simplex virus infection

Matthew S. Gromisch,1 Masayuki Kuraoka,2 Carl F. Ware,3 Steven C. Almo,4 and Betsy C. Herold1

1Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, United States of America

2Department of Immunology, Duke University School of Medicine, Durham, United States of America

3Infectious and Inflammatory Diseases Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States of America

4Department of Biochemistry, Albert Einstein College of Medicine, New York, United States of America

Find articles by Gromisch, M. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, United States of America

2Department of Immunology, Duke University School of Medicine, Durham, United States of America

3Infectious and Inflammatory Diseases Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States of America

4Department of Biochemistry, Albert Einstein College of Medicine, New York, United States of America

Find articles by Kuraoka, M. in: PubMed | Google Scholar |

1Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, United States of America

2Department of Immunology, Duke University School of Medicine, Durham, United States of America

3Infectious and Inflammatory Diseases Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States of America

4Department of Biochemistry, Albert Einstein College of Medicine, New York, United States of America

Find articles by Ware, C. in: PubMed | Google Scholar |

1Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, United States of America

2Department of Immunology, Duke University School of Medicine, Durham, United States of America

3Infectious and Inflammatory Diseases Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States of America

4Department of Biochemistry, Albert Einstein College of Medicine, New York, United States of America

Find articles by Almo, S. in: PubMed | Google Scholar |

1Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, United States of America

2Department of Immunology, Duke University School of Medicine, Durham, United States of America

3Infectious and Inflammatory Diseases Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, United States of America

4Department of Biochemistry, Albert Einstein College of Medicine, New York, United States of America

Find articles by Herold, B. in: PubMed | Google Scholar

Published June 4, 2026 - More info

J Clin Invest. https://doi.org/10.1172/JCI203771.
Copyright © 2026, Gromisch et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published June 4, 2026 - Version history
View PDF
Abstract

Studies with a candidate vaccine deleted in glycoprotein D (ΔgD-2) for herpes simplex virus (HSV) prevention uncovered a role for herpes virus entry mediator (HVEM) in mediating antibody-dependent cell-mediated killing (ADCK) of virally-infected cells. Antibodies elicited by ΔgD-2 passively protect wild-type but not Fc gamma receptor (FcγR) or HVEM knockout (KO) mice. The goals of this study were to identify which cells mediate ADCK and the role of HVEM signaling. Using HVEM ligand and conditional cell-type specific HVEM KO mice combined with in vitro mouse and human cytolytic assays, we demonstrate that ADCK of HSV-infected cells is mediated primarily by neutrophils and requires their expression of HVEM and its ligand, LIGHT. Cytolysis is not associated with granzyme and perforin production but occurs by a trogocytosis-like pathway. Pharmacological inhibition of myosin light-chain kinase (MLCK), which mediates trogocytosis, inhibits cytolysis. Similar results were obtained when human neutrophils were cocultured with HSV-infected cells opsonized with ADCK-containing human immune serum or with breast cancer cells treated with an anti-HER2 trogocytosis mediating antibody. Killing was significantly reduced when an MLCK inhibitor or blocking antibodies to CD16a, HVEM, or LIGHT were added. Together these results define a mechanism of HVEM-enhanced FcγR-mediated neutrophil-dependent ADCK of targets cells.

Supplemental material

View Video S1. Trogocytosis of target cell membrane by WT neutrophils

View Video S2. Impaired trogocytosis of target cell membrane by Hvem-/- neutrophils.

View Video S3. No trogocytosis of target cell membrane by FcγRIV-/- neutrophils.

View Unedited blot and gel images

View

Version history
  • Version 1 (June 4, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts